224
This report describes the first association (exclusive of drug overdose) of symptomatic torsades de pointes occurring with the use of terfenadine in a patient who was taking the recommended prescribed dose of this drug in addition to cefaclor, ketoconazole, and medroxyprogesterone.
 a patient: Subject; symptomatic torsades de pointes: Effect; terfenadine: Treatment; taking the recommended prescribed dose of this drug in addition to cefaclor, ketoconazole, and medroxyprogesterone: Treatment; cefaclor: Treatment.Drug; ketoconazole: Treatment.Drug; medroxyprogesterone: Treatment.Drug; terfenadine: Treatment.Drug; terfenadine: Combination.Drug; cefaclor: Combination.Drug; ketoconazole: Combination.Drug; medroxyprogesterone: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a patient: Subject; symptomatic torsades de pointes: Effect; terfenadine: Treatment; taking the recommended prescribed dose of this drug in addition to cefaclor, ketoconazole, and medroxyprogesterone: Treatment; cefaclor: Treatment.Drug; ketoconazole: Treatment.Drug; medroxyprogesterone: Treatment.Drug; terfenadine: Treatment.Drug; terfenadine: Combination.Drug; cefaclor: Combination.Drug; ketoconazole: Combination.Drug; medroxyprogesterone: Combination.Drug